Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Canelas Vng – page 28

661 clinical trials in Canelas Vng, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Canelas Vng at a glance
661
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

661 trials in Canelas Vng

Open in trial search

Ischaemic stroke+2

Not recruiting

Study on Asundexian for Preventing Ischemic Stroke in Adults After a Stroke or High-Risk Mini-Stroke

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Asundexian
  • Sponsor:Bayer AG

Breast cancer

Not recruiting

Study of Pembrolizumab and Chemotherapy for Patients with HR+/HER2- Advanced Breast Cancer

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Dermatitis atopic

Not recruiting

Study on Long-Term Safety and Efficacy of Amlitelimab for Patients with Moderate to Severe Atopic Dermatitis from Previous Trials

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib, Placebo, and Adalimumab for Patients with Moderate to Severe Rheumatoid Arthritis on Stable Methotrexate Treatment

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Bladder cancer

Not recruiting

Study of Pembrolizumab and BCG for Patients with High-Risk Non-Muscle Invasive Bladder Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE)

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hypertriglyceridaemia+1

Not recruiting

Study of Olezarsen (ISIS 678354) for Patients with High Triglycerides and Heart Disease or Severe High Triglycerides

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Hypertriglyceridaemia

Not recruiting

Study of ISIS 678354 for Patients with Severe Hypertriglyceridemia

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Colitis ulcerative

Not recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Atrial fibrillation

Not recruiting

Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Andexanet Alfa
  • Sponsor:Janssen Cilag International

Arteriosclerosis

Not recruiting

Study on Inclisiran for Preventing Heart Disease in High-Risk Patients

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Sjogren's syndrome

Not recruiting

Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:VIB1116
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Canelas Vng

What the registry says about research in the country

01 Cardiovascular Research

Clinical investigations focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease, exploring innovative therapeutic approaches for this complex patient population.

  • Cardiovascular Outcomes
  • Inflammation Markers
  • Dialysis Patient Care

The research aims to assess treatment effectiveness through monitoring C-reactive protein levels in dialysis patients, potentially leading to improved cardiovascular outcomes in this high-risk group.

02 Nephrology Studies

Specialized research targeting patients with end-stage kidney disease undergoing maintenance dialysis, evaluating novel therapeutic interventions to address cardiovascular complications.

  • Renal Disease Management
  • Dialysis Therapy
  • Cardiovascular Risk

These trials explore intravenous treatments aimed at reducing inflammation markers and improving overall outcomes in dialysis patients.

03 Inflammatory Biomarkers

Investigation of inflammatory markers in cardiovascular disease, specifically focusing on high-sensitivity C-reactive protein as a key indicator in patients undergoing dialysis.

  • Biomarker Analysis
  • Inflammation Control
  • Treatment Response

The research evaluates various dosing strategies to optimize anti-inflammatory responses in patients with combined cardiovascular and kidney conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.